Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X5NX
|
|||
| Former ID |
DAP000945
|
|||
| Drug Name |
Clenbuterol
|
|||
| Synonyms |
Clenbuterolum; Contraspasmin; Planipart; Planipart [veterinary]; Clenbuterol (INN); Clenbuterol [BAN:INN]; Clenbuterolum [INN-Latin]; Contraspasmin (TN); NAB-365; Planipart [veterinary] (TN); (+)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; (+-)-clenbuterol; (-)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; 1-(4-Amino-3,5-dichloro-phenyl)-2-tert-butylamino-ethanol; 1-(4-Amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol; 1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]ethanol; 4-Amino-3,5-dichloro-alpha-(((1,1-dimethylethyl)amino)methyl)benzenemethanol; 4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic breathing disorder [ICD-11: 7A4Z; ICD-10: G47.3] | Approved | [1] | |
| Therapeutic Class |
Bronchodilator Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H18Cl2N2O
|
|||
| Canonical SMILES |
CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O
|
|||
| InChI |
1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3
|
|||
| InChIKey |
STJMRWALKKWQGH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 37148-27-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4445365, 7980738, 8151795, 11335969, 11361208, 11364458, 11367020, 11369582, 11371928, 11374205, 11374656, 11377744, 11462180, 11466373, 11467493, 11486066, 11490790, 11492558, 11492913, 11495378, 15222099, 26756514, 29216418, 29221938, 46508373, 47216807, 47589036, 47885449, 47959784, 48035160, 48110483, 48334530, 48415793, 49698946, 49880554, 50111385, 50111386, 50294329, 51092009, 53789319, 56312093, 56312823, 56312919, 57321457, 57560470, 85084908, 85373776, 85788859, 85856301, 92308851
|
|||
| ChEBI ID |
CHEBI:174690
|
|||
| SuperDrug ATC ID |
R03AC14; R03CC13
|
|||
| SuperDrug CAS ID |
cas=037148279
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-2 (ADRB2) | Target Info | Agonist | [2], [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Salivary secretion | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta2 adrenergic receptor signaling pathway | ||||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Arf6 signaling events | ||||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Vitamin D Receptor Pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drug information of Clenbuterol, 2008. eduDrugs. | |||
| REF 2 | Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7. | |||
| REF 3 | Beta(2)-adrenoceptor stimulation enhances latent transforming growth factor-beta-binding protein-1 and transforming growth factor-beta1 expression in rat hippocampus after transient forebrain ischemia. Neuroscience. 2001;107(4):593-602. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.